- Home
- WGS vs SRRK Comparison
WGS vs SRRK Comparison
Compare WGS & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WGS | SRRK |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WGS | SRRK |
|---|---|---|
| Price | $108.65 | $45.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $138.13 | $49.80 |
| AVG Volume (30 Days) | 554.5K | ★ 995.0K |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $402,190,000.00 | N/A |
| Revenue This Year | $41.17 | N/A |
| Revenue Next Year | $23.53 | $20,320.92 |
| P/E Ratio | $1,499.76 | ★ N/A |
| Revenue Growth | ★ 50.50 | N/A |
| 52 Week Low | $55.17 | $22.71 |
| 52 Week High | $170.87 | $48.28 |
Technical Indicators
Market Signals| Indicator | WGS | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 26.62 | 54.94 |
| Support Level | $103.01 | $40.63 |
| Resistance Level | $113.24 | $46.75 |
| Average True Range (ATR) | 8.17 | 2.29 |
| MACD | -2.74 | 0.01 |
| Stochastic Oscillator | 13.21 | 70.78 |
Price Performance
Historical ComparisonAbout WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.